Companies › Tessa Therapeutics
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2036.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Autologous CD30.CAR-T CD30-directed CAR-T cell therapy | CD30 | Phase 2 | Hodgkin Lymphoma, Adult; Anaplastic Large Cell Lymphoma; Classical Hodgkin Lymphoma | Mar 2036 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04526834 | Autologous CD30.CAR-T | Phase 1 | Anaplastic Large Cell Lymphoma | Oncology | Mar 2036 |
| NCT04268706 | Autologous CD30.CAR-T | Phase 2 | Hodgkin Lymphoma, Adult | Oncology | Mar 2037 |
| NCT05352828 | Autologous CD30.CAR-T | Phase 1 | Classical Hodgkin Lymphoma | Oncology | Dec 2037 |
Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.